Amgen

News

Jazz buys KRAS inhibitors from Redx in $880m deal

Jazz Pharmaceuticals has agreed another pipeline-building deal, this time paying $10 million upfront for rights to a KRAS inhibitor programme from UK biotech Redx Pharma,

News

As Novartis backs off, Amgen said to be after Cytokinetics

Speculation about a takeover play for Cytokinetics isn’t going away, with Amgen the latest company to be linked to the company and its highly-anticipated cardiovascular dr

News

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

The FDA has started a priority review of Amgen’s tarlatamab for small cell lung cancer (SCLC), the lead drug in the company’s pipeline of bispecific T-cell engager (BiTE)

News

Amgen gets Horizon acquisition over the line

Amgen has finally closed its $27.8 billion takeover of Horizon Pharma, which was held up for several months by opposition from financial regulators.

News

FDA panel sceptical on Lumakras confirmatory data

An FDA advisory committee has voted that Amgen’s confirmatory phase 3 trial for KRAS inhibitor Lumakras is not enough to support full approval, but it seems unlikely that

News

WCLC: Amgen eyes first-line use for KRAS drug Lumakras

Amgen is facing a slowdown in uptake of its first-to-market KRAS inhibitor Lumakras as a second-line therapy for KRAS-mutated non-small cell lung cancer (NSCLC), so is und

Jazz buys KRAS inhibitors from Redx in $880m deal

As Novartis backs off, Amgen said to be after Cytokinetics

FDA starts speedy review of Amgen’s lung cancer BiTE therapy

Amgen gets Horizon acquisition over the line

FDA panel sceptical on Lumakras confirmatory data

WCLC: Amgen eyes first-line use for KRAS drug Lumakras

EMA seeks input on virtual alternative to animal test

Using AI-driven synthetic personas to take your insights fur...

Amgen

Editor's Picks